MedPath

Disease Outcomes and Toxicities in Patients With Gastrointestinal and Sarcomatous Malignancies

Recruiting
Conditions
Gastrointestinal Cancer
Sarcoma
Interventions
Other: Survey
Other: Toxicity Assessments
Registration Number
NCT05743426
Lead Sponsor
UNC Lineberger Comprehensive Cancer Center
Brief Summary

This prospective, single-institution, observational study explores disease outcomes and toxicities in subjects with gastrointestinal malignancies and sarcoma (bone and soft tissue) who are being treated with standard-of-care therapies including radiotherapy.

Recent advances in treatment approaches affected disease outcomes and toxicities. Prospective monitoring of disease outcomes and toxicities using standardized assessments will provide information about recent changes in the standard of care and further refine treatment approaches and prospective clinical trial design.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
180
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Single ArmSurveySubjects who are with gastrointestinal malignancies or sarcoma receive radiotherapy.
Single ArmToxicity AssessmentsSubjects who are with gastrointestinal malignancies or sarcoma receive radiotherapy.
Primary Outcome Measures
NameTimeMethod
Disease-free survivalUp to 10 years

Disease-free survival is defined as the length of time after treatment in which the subject survives with no signs or symptoms of cancer.

Secondary Outcome Measures
NameTimeMethod
Quality of life Toronto Extremity Salvage Score (TESS)Up to 10 years

Toronto Extremity Salvage Score (TESS) quality of life questionnaire will be used in subjects with sarcoma.

The TESS is a 30-item patient-reported outcome questionnaire that addresses daily activity limitations including restrictions in body movement, mobility, self-care, and performance of daily tasks. It is scored from 0 (not possible) to 5 (without any problem). Higher scores indicate less functional limitation.

Quality of life PRO-CTCAEUp to 10 years

Quality of life PRO-CTCAE will be evaluated using patient-reported quality of life The PRO-CTCAE is a measurement system that characterizes the frequency, severity, interference, and presence/absence of symptomatic toxicities that include pain, fatigue, nausea, and cutaneous side effects such as rash and hand-foot syndrome, all toxicities that can be meaningfully reported from the patient's perspective.

PRO-CTCAE responses are scored from 0 to 4 (or 0/1 for absent/present).

Local ControlUp to 10 years

Local Control is defined as radiographic and clinical assessments determined by the patient's treating physician.

Adverse EventsUp to 10 years

The NCI Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5 is a descriptive terminology that can be utilized for Adverse Event (AE) reporting. A grading (severity) scale is provided for each AE term. Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL). Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE.

Quality of life EQ-5D-5LUp to 10 years

Quality of life EQ-5D-5L will be evaluated using EQ-5D-5L. The EQ-5D-5L is a QoL assessment that comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels ranging from no problems (Level 1); slight; moderate; severe; and extreme problems (Level 5) to extreme problems.

Trial Locations

Locations (1)

University of North Carolina at Chapel Hill, Department of Radiation Oncology

🇺🇸

Chapel Hill, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath